Search PubMed⌕ Search

Biomedical subjects

J Horejsí

Publications and source records attributed to J Horejsí.

At least 19 recordsLinked to original sources
PubMed2002

[Growth and development in untreated girls with slowly progressing idiopathic central or borderline-onset puberty].

OBJECTIVE: To analyse growth and development of girls with slowly progressive idiopathic precocious or early puberty. DESIGN: Long-term open clinical study. SETTING: Department of Obstetrics and Gynaecology, Second Faculty of Medicine, Charles University, Prague. METHODS: In 20 untreated girls with slowly progressive puberty starting at 6-9 years neurogenic aetiology was excluded. During follow-up period 4.7 +/- 2.2 (2-8.5) years (mean +/- SD; range), sexual development (Tanner criteria), age at menarche, menstrual cycle and auxological parameters were evaluated. RESULTS: 13 girls reached menarche at 11.1 +/- 0.9 years (3.7 +/- 1.1 years after the onset of puberty), earlier than in their mothers (12.9 +/- 1.1 years) and Czech standards (P < 0.05). Menstrual cycle 28 (24-29) days was regular in all 6 girls with gynaecological age > 2 years. In one girl microprolactinoma was diagnosed, therapy with bromocryptine started at the age 14.7 years (3.5 years after menarche). At the onset of follow-up, bone age (TW20) advancement was 1.8 +/- 1.4 years above the chronologic age. Initial prediction of final height (graphic method) was 162.3 +/- 5.5 cm vs final prediction 163.7 +/- 5.1 cm. Final height 162.2 +/- 5.7 cm achieved 7 girls vs target height 163.6 +/- 5.2 cm (NS). CONCLUSION: In untreated girls, menarche occurred later after the first signs of puberty than in normal population, menstrual cycle was regular. Height potential was preserved, final height corresponded with their target height. Not all girls with early and slowly progressive puberty should be treated. Therapy is necessary in organic aetiology, rapid progressive precocious puberty and impaired growth prognosis.

Body Constitution↗
PubMed2001

[Turner syndrome: overview of problems, present status, proposals for care and a protocol for monitoring in childhood, adolescence and adulthood].

BACKGROUND: Girls and adolescents with Turner syndrome (TS) usually receive intensive medical care in a multidisciplinary team, coordinated by paediatric endocrinologist. Majority of them are discharged from specialist clinics following the induction of puberty and attainment of final height. Patients with Turner syndrome have a reduced life expectancy, they are known to have multi-system impairments in addition to the short stature and to the absence of sexual development. Aim of this study is to propos a continuous follow-up by multidisciplinary team of physicians starting in childhood and following the discharge from the paediatric care. METHODS AND RESULTS: This paper highlights the medical and psychosocial problems associated with Turner syndrome in childhood, adolescence and in adulthood. Analysis of these problems served as a background to management strategy. CONCLUSIONS: Women with Turner syndrome are at risk of number of medical problems. Quality of their life and the life expectancy can be improved with increasing awareness to comorbities associated with Turner syndrome. Assisted reproduction technologies has recently offered a chance for pregnancy and delivery of a healthy child also to women with Turner syndrome. Therefore, long-term follow-up by multidisciplinary team of physicians knowledgeable about these medical problems is necessary. Introduction of a centralised system of systematic multidisciplinary approach to patients with Turner syndrome from childhood and adolescence to adulthood seems to be very important.

Adolescent↗
PubMed2001

[Laparoscopic neovaginoplasty--a modification of the Vecchietti operation].

OBJECTIVE: To asses laparoscopic approach to neovaginoplasty. DESIGN: Retrospective clinical study. SETTING: Department of Gynecology and Obstetrics, 2nd Medical Faculty of Charles University. METHODS: Vecchietti's neovaginoplasty is considered to be the most advantageous technique of creating neovagina in vaginal agenesis, because of low perioperational morbidity and quicker recovery. Authors describe own modification of laparoscopic procedure based on designed equipment of themselves. RESULTS: Study evaluates 17 cases of laparoscopic procedures, which are compared with classical laparotomic approach we were experienced in past. Time of surgery was shorter (48 min vs. 66 min) and blood loss was lower (15 ml vs. 50-100 ml) in laparoscopic procedure. Number of complications was lower in this procedure too. There was no difference in length of hospital stay and size of neovagina. CONCLUSION: Laparoscopic modification is safe procedure and comparable with classic operation as regards surgical effect. Both types of procedures are determined for workplaces with experience in special reconstructive surgery and follow-up.

Adolescent↗
PubMed2000

Autoimmune antiovarian antibodies and their impact on the success of an IVF/ET program.

In previous papers, we referred to studies of the influence of antiovarian autoantibodies on menstrual cycle disorders in adolescent girls. We examined autoantibodies against ooplasma, zona pellucida, membrana granulosa, theca folliculi interna, and lutein cells. In infertile women in the IVF/ET program, we studied the positivity of antiovarian antibodies and cytokines, namely, TNF-alpha and IL-1 beta, in follicular fluid correlated with the following subgroups, characterized by the outcome of in vitro fertilization, as follows: G, pregnant; F, fertilized; N, nonfertilized; and O, no oocyte gained. The presence of autoantibodies corresponds to the success or failure of the IVF/ET program. Our results support the hypothesis that antiovarian autoantibodies play an important role in both the endocrine and the reproductive function of the human ovary and that it can influence them negatively.

Adult↗
PubMed2000

[Results from the Registry of Complications in Users of Hormonal Contraception in 1998].

OBJECTIVE: To collect data on the use of hormonal contraception in the Czech Republic in 1998. SETTING: Department of Gynaecology and Obstetrics, Charles University School of Medicine and General University Hospital Prague. METHODS: A total of 2,134 questionnaires were sent to Czech gynaecologists in spring 1999. A total of 418 answers were processed. RESULTS: The estimated number of users presenting in gynaecologist's offices participating in our project was 237,099 women. The most often prescribed contraceptives were monophasic products (54.38%) containing 30-35 micrograms of ethinyl-estradiol (55.21%) with new progestins (53.8%) (norgestimate, gestoden, desogestrel). Regular follow-up of hormonal contraceptive users included the following examinations/tests: blood count in 8.5% offices, ultrasound examination in 8.0% offices, lipid spectrum in 49.8% offices, blood pressure in 74% offices, colposcopy in 97.6% offices, oncological cytology in 98.4% offices and liver tests in 77.1% gynecologist's offices. Only 10.85% of the gynaecologists did not perform lipid tests, almost 20% gynaecologists measured blood pressure only selectively in some users. 80 cases of cardiovascular disease were diagnosed, a figure consistent with an 0.0325% incidence of users. The most frequent complication was deep venous thrombosis (58 cases). The subgroup of women experiencing a cardiovascular event was not characterized by older age, higher body weight, more frequent smoking, or use of products with a higher oestrogen contents. CONCLUSION: There were major differences among gynaecologists in the follow-up of hormonal contraception users. The pattern of the products used varied markedly by regions. The number of diagnosed cardiovascular diseases was very low. Users with a previous a cardiovascular event were only exceptionally carriers of a risk factor.

Cardiovascular Diseases↗
PubMed2000

[Prediction of the effect of a triphasic contraceptive agent with norgestimate on acne].

OBJECTIVE: Prediction of complexion changes in users of triphasic oral contraceptive containing norgestimate. DESIGN: Analysis of data from a prospective multicentre open study. SETTING: Department of Obstetrics and Gynaecology, Charles University, Prague. METHODS: Acne severity was evaluated in users of a triphasic norgestimate-containing contraceptive within a six month period. Based on subjective evaluation of acne, three subgroups of patients were selected: A) users where acne improved or disappeared; B) users in whom acne deteriorated, C) users who newly developed acne. Differences between group A and the other groups were established in the proportion or distribution of parameters related to the etiology of acne: age, weight, weight changes during the study, presence of hirsutism, presence of a regular menstrual cycle prior to the start of hormonal contraception use, and smoking. RESULTS: The effect of the pill use on acne was assessed in a total of 3,990 women. Out of 1,201 women with acne before the start of the study, improvement or disappearance of acne during the study was reported by 940 users (subgroup A) (78.27%). In 221 women (18.40%), the extent of acne remained unaltered whereas it increased (subgroup B) in only 30 women (2.50%). Acne newly developed during the study in 49 women (subgroup C), i.e., in 1.2% of the whole group. Users showing deterioration of acne (subgroup B) were found to have hirsutism less frequently. The subgroup even showed a decrease in mean weight during the study. Users with newly developed acne were--compared with subgroup A--significantly older, had a lower weight at the start of the study, and showed a higher frequency of regular menstrual cycles prior to starting hormonal contraception. The differences in the incidence of clinical parameters in the subgroups reached only borderline statistical significance and, hence, are not relevant. CONCLUSION: An extensive multicentric study confirmed the beneficial effect of a triphasic norgestimate-containing contraceptive on complexion. The presence of clinical parameters related to the etiology of acne does not allow to predict the individual response of the skin to hormonal therapy.

Acne Vulgaris↗
PubMed2000

[Psychosexual development and sex life of women with congenital adrenogenital syndrome].

OBJECTIVE: The aim of the study was to examine the psychosexual development and sexual life of 13 adult women with congenital adrenogenital syndrome. DESIGN: A clinical study. SETTING: Psychiatric clinic, Gynecological clinic and Sexological institute, Medical Faculty of the Charles University in Prague. METHODS: The examination was carried out using a structured interview and three tests: MF (Masculinity and feminity), SFW (Sexual function of women) and SAI (Inventory of sexual arousibility). RESULTS AND CONCLUSION: It was ascertained that only about one third of the patients were coitally active and that the first intercourse was delayed. The results of the questionnaire SFW were in 66% subnormal and an adequate sexual arousability was found only in 40% of examined persons (the test SAI).

Adolescent↗
PubMed1999

Premenarchal and postmenarchal girls with insulin-dependent diabetes mellitus: ovarian and other organ-specific autoantibodies, menstrual cycle.

STUDY OBJECTIVE: To estimate various organ-specific autoantibodies and detect other endocrine autoimmune disorders and menstrual cycle characteristics in girls with Type 1 insulin dependent diabetes mellitus (IDDM). DESIGN: Prospective cohort study from 1993 to 1998, duration 4.5 years. SETTING: Diabetes & Endocrine Clinic of the University Hospital, Motol, Prague. PATIENTS: 53 IDDM girls (group A--43 postmenarchal, group B--10 premenarchal), 15.5 +/- 2.5 (8-19) years old, 6.2 +/- 4.3 years after IDDM onset. MAIN OUTCOME MEASURES: Ovarian autoantibodies directed to ooplasm, zona pellucida, membrana granulosa, theca folliculi interna, and lutein cells, insulin autoantibodies, thyroid peroxidase and thyroglobulin autoantibodies. Menstrual cycle character, endocrine glands disturbance. Diabetes control, body mass index, duration of IDDM. RESULTS: Ovarian autoantibodies in at least one of the followed structures were found in 67.9% of the IDDM girls. In the control group of 21 healthy girls of corresponding age, the positive findings in lutein cells were found in only 4.8% of the girls (P < 0.01 versus IDDM girls). The lutein cells commonly associated with theca folliculi interna cells were the most frequent immunopositive structures in diabetic girls (P < 0.05 versus another positive ovarian autoimmune structure). Autoantibodies directed to ovarian steroid producing cells were frequent in IDDM patients with both irregular and normal menstrual cycles. Irregular menstrual cycles were diagnosed in 27.9% of IDDM girls, polymenorrhea in half of them, and oligomenorrhea in the remainder. Diabetes control in our patients (glycosylated hemoglobin HbA1c in postmenarchal girls 10.1 +/- 2.0%) did not differ between those with regular and those with irregular menstrual cycles. Over a follow-up period one-third of the girls with oligomenorrhea and a long-term noncompliance (HbA1c 13.5%) developed secondary amenorrhea. Insulin autoantibodies were found in 67.8%, thyroid peroxidase autoantibodies in 12.5%, and thyroglobulin autoantibodies in 10.4% of the IDDM girls. Autoimmune thyroiditis was diagnosed in 5 IDDM patients (9.4%); hypothyroidism developed in 3 of them. Menstrual cycle was irregular in 4 of the 5 girls with autoimmune thyroiditis (polymenorrhea in 1, oligomenorrhea in another 3 girls). CONCLUSIONS: An increased incidence of various circulating autoantibodies may be markedly demonstrated in IDDM girls. Their reproductive function might have an important relationship to an evidence of ovarian autoantibodies. Menstrual cycle disturbances could be linked to the poor diabetes control, to the presence of ovarian and other autoantibodies, and also to other autoimmune disease.

Adolescent↗
PubMed1999

[Clinical study of a triphasic contraceptive preparation (Norgestimate 180/215/250 micrograms + ethinylestradiol 35 micrograms) in a population of Czech women].

OBJECTIVE: To assess the efficacy, acceptability and safety of triphasic oral contraceptive pill containing norgestimate 180/215/250 micrograms and ethinylestradiol 35 micrograms. DESIGN AND SETTING: Prospective, open-label, non-comparative, multicenter study in 409 centers in the Czech Republic. METHODS: Body weight, blood pressure, bleeding pattern, headaches, nausea, breast tenderness, acne, pregnancies and side effects were monitored before the start of the treatment, after three and six cycles of oral contraceptive use. Liver function tests were carried out before and after the treatment. RESULTS: Evaluating 26,432 cycles in 4,720 women the theoretical Pearl index was 0.15. There were no significant changes in body weight (61.45 kg before vs 61.58 kg after the treatment). There were clinically significant changes neither in the blood pressure nor in the liver function tests. Evaluating the bleeding pattern there were similar incidences of irregular bleeding/spotting before the treatment and up to the third treatment cycle (16.15%, resp. 17.86%); then the incidence dropped down (8.41% after the third cycle). Amenorhea was very rare (0.41% resp. 0.35% up to, resp. after the third cycle). Decreasing incidences compared to pretreatment state were observed for headache, breast tenderness and acne. The effect on acne was remarkable (28.3% of women complaining of acne before the treatment vs 6.51% after the six treatment cycles). There were no serious adverse events observed during this study. CONCLUSION: Triphasic oral contraceptive pill containing norgestimate and ethinylestradiol proved in a large multicenter study high both efficacy and acceptability.

Adolescent↗
PubMed1999

[Effect of estrogens on final body height in girls with a constitutionally tall stature--risk or benefit?].

OBJECTIVE: Investigation of the effect of a long-term oestrogen treatment on the growth and development of children, elaboration of a theoretical model for remaining growth of girls on a long-term oestrogen therapy predicting reduction of the final height in girls with constitutionally tall stature, analysis of early and late side-effects of therapy. TYPE OF STUDY: Open clinical study. NAME AND PLACE OF DEPARTMENT: Endocrine out-patient clinic of the Second Paediatric Department and gynaecological out-patient clinic for children and adolescents of the Gynaecological-Obstetric Department, Second Medical School--Charles University and University Hospital Prague--Motol. METHOD: Elaboration of theoretical model for remaining growth of girls on a long-term oestrogen therapy was based on an analysis of the remaining growth of upper and lower body segment of healthy Czech girls. RESULTS: The extent of assumed reduction of the final height in girls with constitutionally tall stature treated with oestrogen declines with advancing age at the onset of treatment. The optimal age for the onset of treatment is between 10 and 11 years. CONCLUSION: Treatment can be recommended only in girls with growth prediction above 185 cm and serious psychological difficulties resulting from excessive height, always after careful analysis of the biological development and growth prediction. In every case it is necessary to evaluate the possible benefit of treatment in relation to potential risks. The greatest problem is according to the authors late onset and overrating of the therapeutic possibilities.

Adolescent↗
PubMed1997

Acquired clitoral enlargement. Diagnosis and treatment.

Clitoral hypertrophy is usually seen in congenital malformations, specifically in intersexual stages of hormonal expression. Acquired clitoral hypertrophy is a relatively rare condition, and data in the literature concerning this problem are sparse. Articles usually consist only of case reports. Among the contributing factors in the etiology of acquired clitoral hypertrophy, the following three are the most frequent: (1) endocrinopathies including virilizing tumors of the ovaries or adrenals, (2) neurofibromatosis (of both clitoral subcutis and corpora cavernosa), and (3) pseudohypertrophy of the clitoris. The first step in correcting acquired clitoral enlargement must be to determine and stop the cause of the hypertrophy, followed by a period of simple observation. If clitoral enlargement does not disappear over time, surgical correction is necessary.

Clitoris↗